G1 THERAPEUTICS (NASDAQ:GTHX) major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $20.01, for a total transaction of $4,002,000.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

G1 THERAPEUTICS (GTHX) traded up $0.28 during trading on Wednesday, hitting $20.25. 81,200 shares of the stock traded hands, compared to its average volume of 95,766. G1 THERAPEUTICS has a 52 week low of $12.04 and a 52 week high of $28.67.

COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/22/medimmune-ventures-inc-sells-200000-shares-of-g1-therapeutics-gthx-stock.html.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System acquired a new stake in G1 THERAPEUTICS during the 3rd quarter valued at $319,000. Schwab Charles Investment Management Inc. acquired a new position in G1 THERAPEUTICS during the 3rd quarter worth $364,000. American International Group Inc. acquired a new position in G1 THERAPEUTICS during the 3rd quarter worth $130,000. Chartwell Investment Partners LLC lifted its position in shares of G1 THERAPEUTICS by 5.0% in the 3rd quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock worth $2,303,000 after buying an additional 4,388 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in G1 THERAPEUTICS in the 3rd quarter valued at about $568,000. 40.23% of the stock is owned by institutional investors and hedge funds.

Several brokerages have weighed in on GTHX. Cowen and Company restated a “buy” rating on shares of G1 THERAPEUTICS in a research report on Wednesday, August 9th. Zacks Investment Research lowered shares of G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. G1 THERAPEUTICS has an average rating of “Buy” and a consensus price target of $29.75.


G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.